San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Blue Note Therapeutics is raising $50,000,000.00 in new funding. Sources indicate as part of senior management President, Geoffrey Eich played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Blue Note Therapeutics
Blue Note Therapeutics is a prescription digital therapeutics company singularly dedicated to helping patients live better. Blue Note is merging deep scientific and clinical expertise with digital and gaming innovation to transform care for seriously ill patients. Working closely with leading medical researchers and patient advocacy organizations, Blue Note is creating clinically-validated, FDA-approvable prescription-only digital devices to treat the burden of illness. Our team aims to make therapy available to any patient, at any time, on patients own mobile devices. Patients and clinicians are our partners in developing programs that are highly effective and engaging so that it is easier for patients to stick with them.

To learn more about Blue Note Therapeutics, visit http://bluenotetherapeutics.com/

Contact:
Geoffrey Eich, President
415-200-3697
https://www.linkedin.com/in/geoffreyeich/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved